A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
Status:
RECRUITING
Trial end date:
2026-02-28
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, ascending multiple oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects and/or subjects with stable schizophrenia.